Prostate Cancer

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial.

An investigational prostate cancer vaccine has shown potential to improve survival in patients with metastatic castration-resistant prostate cancer (CRPC).

Prostate cancer prognosis remains poor for patients who have a prostate-specific antigen level ≥100 ng/mL at discovery, a review of cancer registry data showed.

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute (NCI), gives an overview of the adverse event profile for PROSTVAC.

Progression-free survival doubled in men with metastatic castration-resistant prostate cancer with no chemotherapy exposure who were treated with abiraterone acetate plus prednisone versus prednisone alone.

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Daniel J. George, MD, from the Duke Cancer Institute, elaborates on the incorporation of radium-223 into the treatment of patients with metastatic castration-resistant prostate cancer.

The quest to deliver optimal radiation therapy for patients with prostate cancer has led to a variety of advances in technologies and techniques, yet key questions remain unanswered.

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Challenges remain regarding the mechanisms of docetaxel resistance, whether combination studies continue to make sense, and how the sequencing of docetaxel may impact toxicity and efficacy.